Cefpodoxime

Cefpodoxime

SCHEMBL2015784

COCC1=C(C(=O)O)N2C(=O)C(NC(=O)/C(=N\OC)c3csc(N)n3)[C@@H]2SC1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

dacAdacBdacCftsImrcAmrcBmrdA

The experimentally established mechanism targets of Cefpodoxime. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NR1I2 O75469 6/20 1.00
HTR2C P28335 1/20 1.00
MAPT P10636 3/20 0.87
PPARG P37231 2/20 0.87
SLC22A6 Q4U2R8 2/20 0.87
SLC22A8 Q8TCC7 2/20 0.87
SLC22A11 Q9NSA0 2/20 0.87
ALB P02768 1/20 0.87
PTGS1 P23219 2/20 0.75
ABCB11 O95342 1/20 0.75
PDE4D Q08499 1/20 0.75
TDP1 Q9NUW8 6/20 0.74
APEX1 P27695 3/20 0.74
ABCC4 O15439 2/20 0.74
HSD17B10 Q99714 2/20 0.74
LMNA P02545 2/20 0.74
L3MBTL1 Q9Y468 2/20 0.74
CYP1A2 P05177 1/20 0.74
PKM P14618 1/20 0.74
ALDH1A1 P00352 1/20 0.74

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Cefpodoxime SCHEMBL69122 1.00 NR1I2 (1.00) NR1I2HTR2CMAPTPPARGSLC22A6
Cefpodoxime SCHEMBL16072818 1.00 NR1I2 (1.00) NR1I2HTR2CMAPTPPARGSLC22A6
Cefpodoxime SCHEMBL6688590 1.00 NR1I2 (1.00) NR1I2HTR2CMAPTPPARGSLC22A6
Cefpodoxime SCHEMBL13189562 1.00 NR1I2 (1.00) NR1I2HTR2CMAPTPPARGSLC22A6
Cefpodoxime SCHEMBL27072 1.00 NR1I2 (1.00) NR1I2HTR2CMAPTPPARGSLC22A6
Cefpodoxime SCHEMBL2015780 1.00 NR1I2 (1.00) NR1I2HTR2CMAPTPPARGSLC22A6
Cefpodoxime SCHEMBL3014534 0.99 NR1I2 (0.98) NR1I2HTR2CMAPTPPARGSLC22A6
Cefpodoxime SCHEMBL8868198 0.99 NR1I2 (0.98) NR1I2HTR2CMAPTPPARGSLC22A6
Cefpodoxime SCHEMBL6238484 0.99 NR1I2 (0.98) NR1I2HTR2CMAPTPPARGSLC22A6
Cefpodoxime SCHEMBL5265715 0.99 NR1I2 (0.98) NR1I2HTR2CMAPTPPARGSLC22A6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060135761-A1 4-halo-2-oxyimino-3-oxo butyric acid-N,N-dimethyl formiminium chloride chlorosulfate; cephalosporins that may be prepared from the intermediate include cefdinir, cefditoren pivoxil, cefepime, cefetamet pivoxil, cefixime, cefmenoxime, cefodizime, cefoselis, cefotaxime, cefpirome, cefpodoxime proxetil, etc LUPIN LIMITED (IN) 2006-06-22 US claimed
EP-1575913-A1 NOVEL INTERMEDIATES FOR SYNTHESIS OF CEPHALOSPORINS AND PROCESS FOR PREPARATION OF SUCH INTERMEDIATES Lupin Limited (IN) 2005-09-21 EP claimed
WO-2004058695-A1 NOVEL INTERMEDIATES FOR SYNTHESIS OF CEPHALOSPORINS AND PROCESS FOR PREPARATION OF SUCH INTERMEDIATES LUPIN LIMITED (IN) 2004-07-15 WO claimed
WO-2011077217-A1 AN IMPROVED PROCESS FOR THE PREPARATION OF CEFPODOXIME ACID NECTAR LIFESCIENCES LTD. (IN) 2011-06-30 WO disclosed
US-20060135761-A1 4-halo-2-oxyimino-3-oxo butyric acid-N,N-dimethyl formiminium chloride chlorosulfate; cephalosporins that may be prepared from the intermediate include cefdinir, cefditoren pivoxil, cefepime, cefetamet pivoxil, cefixime, cefmenoxime, cefodizime, cefoselis, cefotaxime, cefpirome, cefpodoxime proxetil, etc LUPIN LIMITED (IN) 2006-06-22 US disclosed
EP-1575913-A1 NOVEL INTERMEDIATES FOR SYNTHESIS OF CEPHALOSPORINS AND PROCESS FOR PREPARATION OF SUCH INTERMEDIATES Lupin Limited (IN) 2005-09-21 EP disclosed
EP-1228074-B1 METHOD OF PREPARING HIGHLY PURE CEFPODOXIME PROXETIL HANMI PHARM IND CO LTD (KR) 2005-06-15 EP disclosed
EP-1389187-A4 PROCESS FOR THE PREPARATION OF CEFPODOXIME ACID RANBAXY LAB LTD (IN) 2005-03-16 EP disclosed
US-20050020561-A1 Process for the preparation of cefpodoxime acid RANBAXY LABORATORIES LIMITED (IN) 2005-01-27 US disclosed
WO-2004058695-A1 NOVEL INTERMEDIATES FOR SYNTHESIS OF CEPHALOSPORINS AND PROCESS FOR PREPARATION OF SUCH INTERMEDIATES LUPIN LIMITED (IN) 2004-07-15 WO disclosed
US-20040087787-A1 Novel thioester derivatives of thiazolyl acetic acid and their use in the preparation of cephalosporin compounds ORCHID CHEMICALS & PHARMACEUTICALS LIMITED (IN) 2004-05-06 US disclosed
WO-2003004477-A1 1,3,4-OXADIAZOL-2-YL THIOESTERS AND THEIR USE FOR ACYLATING 7-AMINOCEPHALOSPORINS ORCHID CHEMICALS & PHARMACEUTICALS LIMITED (IN) 2003-01-16 WO disclosed
WO-2002083634-A2 PROCESS FOR THE PREPARATION OF CEFPODOXIME ACID RANBAXY LABORATORIES LIMITED (IN) 2002-10-24 WO disclosed
EP-1228074-A1 METHOD OF PREPARING HIGHLY PURE CEFPODOXIME PROXETIL Hanmi Pharm. Co., Ltd. (KR) 2002-08-07 EP disclosed
WO-2002053563-A1 NOVEL THIOESTER DERIVATIVES OF THIAZOLYL ACETIC ACID AND THEIR USE IN THE PREPARATION OF CEPHALOSPORIN COMPOUNDS ORCHID CHEMICALS & PHARMACEUTICALS LIMITED (IN) 2002-07-11 WO disclosed
US-6388070-B1 CHEMICAL INTERMEDIATE ORCHID CHEMICALS & PHARMACEUTICALS LTD. (IN) 2002-05-14 US disclosed
US-6384215-B1 REACTING 4-HALO-2-METHOXYIMINO-3-OXO-BUTYRIC ACID WITH 2-MERCAPTO-1,3,4-OXADIAZOLE TO PRODUCE 2-MERCAPTO-1,3,4-OXADIAZOLYL-4-HALO-2-METHOXYIMINO BUTYRIC ACID; REACTING WITH 7-AMINO-CEPHEM CARBOXYLIC ACID AND THIOUREA ORCHID CHEMICALS & PHARMACEUTICALS LTD. (IN) 2002-05-07 US disclosed
EP-1178992-A2 PROCESS FOR THE PREPARATION OF CEFPODOXIME ACID Ranbaxy Laboratories, Limited (IN) 2002-02-13 EP disclosed
WO-2001034611-A1 METHOD OF PREPARING HIGHLY PURE CEFPODOXIME PROXETIL HANMI PHARM. CO., LTD. (KR) 2001-05-17 WO disclosed
WO-2000068234-A2 PROCESS FOR THE PREPARATION OF CEFPODOXIME ACID RANBAXY LABORATORIES LIMITED (IN) 2000-11-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050020561-A1 Process for the preparation of cefpodoxime acid CYP2F1, CYP4F11, CYP51A1 NR1I2 2108/4885HTR2C 3939/4885MAPT 3974/4885
US-20040087787-A1 Novel thioester derivatives of thiazolyl acetic acid and their use in the preparation of cephalosporin compounds ACOT7, ACACA, COASY NR1I2 2701/4885HTR2C 4739/4885MAPT 2940/4885
US-20060135761-A1 4-halo-2-oxyimino-3-oxo butyric acid-N,N-dimethyl formiminium chloride chlorosulfate; cephalosporins that may be prepared from the intermediate include cefdinir, cefditoren pivoxil, cefepime, cefetamet pivoxil, cefixime, cefmenoxime, cefodizime, cefoselis, cefotaxime, cefpirome, cefpodoxime proxetil, etc CYP2F1, CYP2W1, CYP4F11 NR1I2 154/4885HTR2C 1066/4885MAPT 4597/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.